DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials

by Morgan C, Jin X, Yu X, De Rosa S, Kublin J, Metch B, Keefer M, NIAID H
Published 2012-09-01

P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa

by Roux S, Moodie Z, Metch B, Mlisana K, Nchabeleng M, Bekker L, Churchyard G, Gray G, Allen MA, Mathebula M, Bennie T, Kublin J
Published 2009-10-01

P15-13. HVTN 503(Phambili) trial discontinuation of enrolment/vaccination: the impact on trial participant attitudes to vaccine trials and scientific research

by Magagula D, Latka M, De Bruyn G, Churchyard G, Nchabaleng M, Mlisana K, Gray G, Roux S, Middelkoop K, Mark D, Kublin J, Allen M, Bekker L
Published 2009-10-01

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?

by Moodie Z, Metch B, Bennie T, Latka M, Mathebula M, Roux S, de Bruyn G, Mlisana K, Nchabeleng M, Churchyard G, Bekker L, Gray GE, Allen M, Eaton N, Kublin J
Published 2009-10-01